

Interlocutory Orders, Etc.

IN THE MATTER OF

HOLCIM LTD.

AND

LAFARGE S.A.

Docket No. C-4519. Order, July 12, 2017

Letter Order approving amendments to the Essroc Divestiture Agreement.

LETTER ORDER APPROVING PETITION

Andrew M. Lacy, Esquire
Simpson Thacher & Bartlett LLP

Re: *Holcim Ltd. and Lafarge S.A.*, Docket No. C-4519

Dear Mr. Lacy:

This letter is in reference to the Petition of LafargeHolcim For Approval of Amendments Related to the Essroc Divestiture Agreement (“Petition”) that you filed with the Commission on behalf of LafargeHolcim Ltd. on May 19, 2017.

Pursuant to Rule 2.41(f) of the Commission’s Rules of Practice, the Commission has determined to approve the Petition of LafargeHolcim to amend the Essroc Divestiture Agreement, as proposed in the Petition. In according its approval, the Commission has relied upon the information submitted and the representations made in connection with the Petition, and has assumed them to be accurate and complete.

By direction of the Commission.

Interlocutory Orders, Etc.

IN THE MATTER OF

**TEVA PHARMACEUTICAL INDUSTRIES LTD.
AND
ALLERGAN PLC***Docket No. C-4589. Order, July 18, 2017*

Letter notifying Teva Pharmaceutical Industries Ltd. of the Commission's decision to waive prior approval and public comment regarding modifications to the supply agreement.

**LETTER WAIVING PRIOR APPROVAL AND COMMENT FOR
MODIFICATIONS TO A SUPPLY AGREEMENT**

Ian R. Conner, Esq.
Kirkland & Ellis LLP

Re: In the Matter of Teva Pharmaceutical Industries Ltd, et al.
Docket No. C.4589

Dear Mr. Conner:

This is in reference to a request for approval filed by Teva Pharmaceutical Industries Ltd. ("Teva") and received on June 27, 2017 ("Request"). Pursuant to the Decision and Order in Docket No. C-4589, Teva requests Commission approval of its proposal to make certain modifications to the supply agreement between Dr. Reddy's, a Commission-approved acquirer in this matter, and Teva.

After consideration of Teva's Request and pursuant to the authority delegated to me under Rule 2.41(f)(5)(ii) of the Commission's Rules of Practice, 16 C.F.R. § 2.41(f)(5)(ii), I hereby waive the requirements for Commission approval and the public comment period for the modifications to the supply agreement described in Teva's Request

If you have further questions, please contact David von Nirschl, the Compliance staff attorney assigned to this matter. Mr. von Nirschl can be reached at 202-326-3213 or dnirschl@ftc.com.